Published in Liver Transpl on January 01, 2005
Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol (2010) 1.41
Treatment of acute liver failure in mice by hepatocyte xenotransplantation. Cell Transplant (2010) 0.77
Experimental hepatocyte xenotransplantation--a comprehensive review of the literature. Xenotransplantation (2015) 0.77
Cellular Transplantation for Liver Diseases. Gastroenterology Res (2008) 0.75
Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology (2008) 3.99
Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol (2002) 3.32
Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology (2006) 2.04
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med (2004) 1.92
Biological implications of cell fusion. Nat Rev Mol Cell Biol (2005) 1.87
Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant (2003) 1.86
Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol (2004) 1.62
Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients. Eur Heart J (2008) 1.56
Apoptosis and cellular activation in the pathogenesis of acute vascular rejection. Circ Res (2002) 1.56
New technologies for organ replacement and augmentation. Mayo Clin Proc (2005) 1.48
Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation. Gastroenterology (2003) 1.48
Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol (2003) 1.47
Xenotransplantation and the future of renal replacement. J Am Soc Nephrol (2004) 1.47
Conditional signaling by Toll-like receptor 4. FASEB J (2005) 1.42
Barriers to the successful treatment of liver disease by hepatocyte transplantation. J Hepatol (2010) 1.41
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
Immunosuppression by embryonic stem cells. Stem Cells (2007) 1.38
Patient privacy, photographs, and publication. JAMA Facial Plast Surg (2013) 1.37
Spinal meningiomas in patients younger than 50 years of age: a 21-year experience. J Neurosurg (2003) 1.35
Bilateral vallecular cysts as a cause of Dysphagia: case report and literature review. Int J Otolaryngol (2010) 1.28
Temporal analysis of signaling pathways activated in a murine model of two-kidney, one-clip hypertension. Am J Physiol Renal Physiol (2009) 1.27
Accommodation: preventing injury in transplantation and disease. J Immunol (2004) 1.25
Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. Hepatology (2009) 1.23
Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant (2005) 1.23
Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue. Cancer Res (2007) 1.20
The double-edged sword of activation-induced cytidine deaminase. J Immunol (2005) 1.20
B cell-dependent TCR diversification. J Immunol (2004) 1.18
Evidence for the pivotal role of endogenous toll-like receptor 4 ligands in liver ischemia and reperfusion injury. Transplantation (2008) 1.17
Dimerization of MLH1 and PMS2 limits nuclear localization of MutLalpha. Mol Cell Biol (2003) 1.14
Fitness of cell-mediated immunity independent of repertoire diversity. J Immunol (2007) 1.11
Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem (2002) 1.09
Selective activation of TACI by syndecan-2. Blood (2005) 1.09
Accommodation in organ transplantation. Curr Opin Organ Transplant (2008) 1.08
Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation (2004) 1.08
Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension. Am J Physiol Renal Physiol (2012) 1.05
A genetic basis for the "Adonis" phenotype of low adiposity and strong bones. FASEB J (2004) 1.05
ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation (2003) 1.04
LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. Am J Pathol (2011) 1.04
Accommodation of grafts: implications for health and disease. Hum Immunol (2007) 1.04
Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol (2003) 1.03
C4d and the fate of organ allografts. J Am Soc Nephrol (2002) 1.01
Infection-induced proteolysis of PGRP-LC controls the IMD activation and melanization cascades in Drosophila. FASEB J (2008) 1.01
Effacing of the T cell compartment by cardiac transplantation in infancy. J Immunol (2006) 1.00
TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow. Blood (2011) 1.00
Spontaneous fusion of cells between species yields transdifferentiation and retroviral transfer in vivo. FASEB J (2004) 0.99
The etiology of sepsis: turned inside out. Trends Mol Med (2005) 0.98
Direct measurement of lymphocyte receptor diversity. Nucleic Acids Res (2003) 0.98
Short-term immunosuppression and surgical neoangiogenesis with host vessels maintains long-term viability of vascularized bone allografts. J Orthop Res (2007) 0.98
Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer (2006) 0.97
Selective suppression of Toll-like receptor 4 activation by chemokine receptor 4. FEBS Lett (2005) 0.97
Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res (2003) 0.96
Propagation and control of T cell responses by heparan sulfate-bound IL-2. J Immunol (2003) 0.96
Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model. Am J Physiol Renal Physiol (2013) 0.94
Selective fiberoptic left main-stem intubation to treat bronchial laceration in an extremely low birth weight neonate. Int J Pediatr Otorhinolaryngol (2010) 0.92
T cell recognition and immunity in the fetus and mother. Cell Immunol (2007) 0.92
The paradoxical functions of B cells and antibodies in transplantation. J Immunol (2013) 0.92
Complement-dependent control of teratoma formation by embryonic stem cells. J Immunol (2006) 0.91
Oral cavity and oropharynx squamous cell carcinoma with metastasis to the parotid lymph nodes. Oral Oncol (2010) 0.91
AS30D model of hepatocellular carcinoma: tumorigenicity and preliminary characterization by imaging, histopathology, and immunohistochemistry. Cardiovasc Intervent Radiol (2012) 0.90
Membrane barrier of a porcine hepatocyte bioartificial liver. Liver Transpl (2003) 0.90
Intrinsic resistance of hepatocytes to complement-mediated injury. J Immunol (2005) 0.90
Differential regulation of endothelial cell activation by complement and interleukin 1alpha. Circ Res (2006) 0.89
In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem (2006) 0.89
Disparate roles of marrow- and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammation. Sci Rep (2012) 0.88
A national conference to determine research priorities in pediatric solid organ transplantation. Pediatr Transplant (2008) 0.88
Membrane pore size impacts performance of a xenogeneic bioartificial liver. Transplantation (2003) 0.88
Pivotal advance: endogenous pathway to SIRS, sepsis, and related conditions. J Leukoc Biol (2007) 0.88
Combined effect of hyperfiltration and renin angiotensin system activation on development of chronic kidney disease in diabetic db/db mice. BMC Nephrol (2014) 0.88
Redox signaling is an early event in the pathogenesis of renovascular hypertension. Int J Mol Sci (2013) 0.88
Pathways to acute humoral rejection. Am J Pathol (2004) 0.87
Accommodation in renal transplantation: unanswered questions. Curr Opin Organ Transplant (2010) 0.87
Potential applications and prospects for cardiac xenotransplantation. J Heart Lung Transplant (2004) 0.87
Affinity maturation of antibodies requires integrity of the adult thymus. Eur J Immunol (2011) 0.86
Molecular and cellular mechanisms of mammalian cell fusion. Adv Exp Med Biol (2011) 0.85
Basic mechanisms of humoral rejection. Pediatr Transplant (2005) 0.85
Evaluation of strategies to reduce radiation dose in perfusion CT imaging using a reproducible biologic phantom. AJR Am J Roentgenol (2013) 0.84
Monocyte-mediated T cell suppression by HIV-2 envelope proteins. Eur J Immunol (2007) 0.83
TACI deficiency enhances antibody avidity and clearance of an intestinal pathogen. J Clin Invest (2014) 0.83
Fusion of approaches to the treatment of organ failure. Am J Transplant (2004) 0.83
New insight into the pathogenesis of sepsis and the sepsis syndrome. Surgery (2005) 0.82
Confirmation of research publications reported by neurological surgery residency applicants. Surg Neurol (2003) 0.82
The footprint of antibody bound to pig cells: evidence of complex surface topology. Biochem Biophys Res Commun (2003) 0.82
Humoral rejection and endothelial cell activation, 2001. Xenotransplantation (2002) 0.81
Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. Transplantation (2002) 0.81
Toward development and production of human T cells in swine for potential use in adoptive T cell immunotherapy. Tissue Eng Part A (2009) 0.81